The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Neoadjuvant chemotherapy with camrelizumab in esophageal SCC: ESCORT-NEO trial
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on the ESCORT-NEO trial, a Phase III study (ChiCTR2000040034) evaluating the role of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab in resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). The multicenter, randomized trial included three groups with different neoadjuvant therapies, followed by surgery and adjuvant treatment. The co-primary endpoints were pathological complete response (pCR) rate and event-free survival. The study enrolled 391 patients, showing significantly higher pCR rates in the groups receiving neoadjuvant camrelizumab with chemotherapy compared to neoadjuvant chemotherapy alone. The combination demonstrated superior efficacy with a tolerable safety profile in resectable LA-ESCC. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
